{"gene":"ABCD2","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1997,"finding":"ABCD2 (ALDRP) encodes a 740-amino-acid peroxisomal membrane protein that is a half-ABC transporter with 62.8% identity to ABCD1 (ALDP), predicted to form homodimers or heterodimers with other peroxisomal ABC transporters. mRNA is expressed predominantly in brain and heart.","method":"cDNA cloning, sequence analysis, tissue expression profiling","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, cDNA cloning with sequence/expression analysis, no functional reconstitution","pmids":["9345306"],"is_preprint":false},{"year":1999,"finding":"Human ABCD2 (ALDRP) localizes exclusively to peroxisomes. The gene spans 33 kb on chromosome 12q12, consists of 10 exons, and its promoter contains a novel motif conserved among peroxisomal ABC transporters. ALDRP transfection into X-ALD cells complements the VLCFA oxidation defect.","method":"Subcellular fractionation, immunolocalization, genomic sequencing, functional complementation in ABCD1-deficient cells","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2/3 — direct localization plus functional complementation in cell model, single lab","pmids":["10329405"],"is_preprint":false},{"year":2000,"finding":"The ABCD2 promoter (1.3 kb of human and mouse 5'-upstream region) has functional promoter activity and is upregulated by 9-cis-retinoic acid and forskolin. No PPARα response element was detected in the promoter by transfection assays.","method":"Luciferase reporter assays, promoter deletion/transfection in cell lines","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 3 — reporter assays with multiple inducers, single lab","pmids":["11087670"],"is_preprint":false},{"year":2001,"finding":"Fibrate induction of ABCD2 is PPARα-dependent in vivo (absent in PPARα-knockout mice), but no functional PPRE motif could be identified in the ABCD2 promoter by gel-shift assay and transfection of COS-7 cells, indicating a non-canonical PPARα-dependent regulatory mechanism.","method":"PPARα knockout mice treated with fenofibrate, gel-shift assay, promoter transfection in COS-7 cells","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo genetic knockout combined with in vitro promoter assays, single lab","pmids":["11422379"],"is_preprint":false},{"year":2002,"finding":"ABCD2 is transcriptionally induced by sterol depletion via activation of sterol regulatory element-binding proteins (SREBPs). A functional sterol regulatory element (SRE) was identified in the proximal ABCD2 promoter by reporter gene studies, site-directed mutagenesis, and gel-shift assays. ABCD2 induction by sterol depletion significantly reduced VLCFA accumulation in X-ALD fibroblasts.","method":"Real-time PCR, reporter gene assays, site-directed mutagenesis, gel-shift assay (EMSA), functional VLCFA measurement in patient fibroblasts","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including mutagenesis, EMSA, and functional rescue in patient cells","pmids":["12374760"],"is_preprint":false},{"year":2003,"finding":"ABCD2 is induced by thyroid hormone (T3) via TRβ. The ABCD2 promoter contains a functional thyroid hormone response element that binds RXR/TRβ heterodimer, mediating T3 responsiveness. T3 induces ABCD2 in liver of normal rats but not TRβ-knockout mice, and in differentiated oligodendrocytes (CG4 cells) but not astrocytes. T3 induction in ABCD1-deficient fibroblasts normalized VLCFA β-oxidation.","method":"Gel-shift assay (RXR/TRβ binding), TRβ-knockout mice, liver induction in vivo, cell-type specific induction, β-oxidation assay in ABCD1-deficient fibroblasts","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic knockout, multiple cell types, functional rescue, multiple orthogonal methods","pmids":["12761339"],"is_preprint":false},{"year":2004,"finding":"ABCD2 functionally overlaps with ABCD1 in vivo: overexpression of ABCD2 in Abcd1-knockout mice prevents VLCFA accumulation and neurodegenerative pathology (axonal damage followed by myelin degeneration). Double Abcd1/Abcd2 knockout mice display earlier onset and more severe disease, including inflammatory reaction, demonstrating functional redundancy between the two transporters.","method":"Transgenic overexpression of ABCD2 in Abcd1-KO mice, Abcd1/Abcd2 double knockout generation, histopathology, VLCFA measurement","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic epistasis with multiple knockout and transgenic models, multiple phenotypic readouts","pmids":["15489218"],"is_preprint":false},{"year":2005,"finding":"Abcd2-knockout mice develop late-onset cerebellar and sensory ataxia with loss of Purkinje cells and dorsal root ganglia degeneration, correlating with VLCFA accumulation in those cells. The underlying pathological mechanism involves mitochondrial, Golgi, and endoplasmic reticulum damage, demonstrating disturbed organelle cross-talk as a downstream consequence of ABCD2 loss.","method":"Abcd2-knockout mouse generation and characterization, histopathology, electron microscopy of organelles, VLCFA measurement","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — constitutive knockout with defined cellular and ultrastructural phenotype, replicated across tissue types","pmids":["16223892"],"is_preprint":false},{"year":2005,"finding":"LXRα acts as a negative modulator of Abcd2 expression by competing with SREBP1c at overlapping SRE/DR-4 binding sites in the Abcd2 promoter. SREBP1c induces adipose Abcd2, while concurrent LXRα activation suppresses hepatic Abcd2. LXRα/β-deficient mice show greatly elevated Abcd2 induction, confirming LXRα as a repressor.","method":"EMSA with nuclear extracts, LXRα/β-knockout mice, fasting-refeeding and cholesterol loading paradigms, cell culture reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — in vivo knockout plus in vitro EMSA and reporter assays, multiple orthogonal approaches","pmids":["16249184"],"is_preprint":false},{"year":2006,"finding":"ABCD2 (ALDRP) expressed in Sf21 insect cells via baculovirus shows ATPase activity in membrane fractions and nucleotide-binding capacity. Unlike ABCD1 which binds both ADP and ATP, ABCD2 binds ADP but has negligible affinity for ATP, suggesting functional differences in nucleotide binding between the two paralogs.","method":"Baculovirus-mediated overexpression in Sf21 cells, ATPase activity assay, ATP/ADP-agarose binding, immunoelectron microscopy, subcellular fractionation","journal":"Biological & pharmaceutical bulletin","confidence":"Medium","confidence_rationale":"Tier 2 — direct biochemical activity assay in overexpression system, single lab","pmids":["16946495"],"is_preprint":false},{"year":2007,"finding":"Loss of Abcd2 (not Abcd1) causes oxidative damage in the mouse adrenal gland: Abcd2 knockout mice show increased mitochondrial manganese superoxide dismutase immunoreactivity and spontaneous premature ceroid deposition (a marker of oxidative damage) predominantly in adrenal medullary cells, indicating a specific role for ABCD2 in limiting oxidative stress in adrenal tissue.","method":"Abcd1 and Abcd2 single/double knockout mice, immunohistochemistry for oxidative stress markers (MnSOD, ceroid), comparative genotype analysis","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2 — comparative knockout analysis with defined cellular phenotype, single lab","pmids":["17260006"],"is_preprint":false},{"year":2007,"finding":"DHEA induces Abcd2 and Abcd3 expression in rodent liver in vivo and in primary rat hepatocytes in vitro, but this induction of Abcd2 is independent of PPARα (unlike Abcd3), revealing a PPARα-independent pathway for ABCD2 regulation.","method":"In vivo DHEA treatment, primary hepatocyte cultures, PPARα-knockout mice comparison, RT-PCR","journal":"Biochimie","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo and in vitro with PPARα-null comparison, single lab","pmids":["17686565"],"is_preprint":false},{"year":2008,"finding":"ABCD2 plays a role in degradation of long-chain saturated and omega-9 monounsaturated fatty acids and in the synthesis of docosahexaenoic acid (DHA). Abcd2-knockout mouse brain slices show defective VLCFA β-oxidation ex vivo using radiolabeled hexacosanoic acid and DHA precursor, distinct from the substrate profile of Abcd1-knockout.","method":"Fatty acid profiling in knockout mouse organs and primary neurons, radiolabeled β-oxidation assay in brain slices, dietary challenge experiments","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (profiling + functional β-oxidation with radiolabeled substrates) in knockout models","pmids":["18854420"],"is_preprint":false},{"year":2008,"finding":"TRα and TRβ bind the overlapping SRE/DR-4 motif in the ABCD2 promoter and differentially modulate SREBP1-dependent ABCD2 activation: unliganded TRβ (but not TRα) represses ABCD2 independently of DNA binding, while T3-dependent activation requires TRα and intact SRE/DR-4 motifs. EMSA with nuclear extracts supports direct TR-SREBP1 interaction at this element.","method":"EMSA, TRα and TRβ knockout mice, T3 manipulation (fasting/refeeding), reporter gene assays, RT-PCR in liver","journal":"European journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — multiple receptor knockout mouse models plus EMSA and reporter assays","pmids":["18834645"],"is_preprint":false},{"year":2008,"finding":"Silencing of Abcd1 and Abcd2 by siRNA in mouse primary astrocytes causes VLCFA accumulation and induces an inflammatory response (iNOS, inflammatory cytokines) mediated by NF-κB, AP-1, and C/EBP transcription factors, establishing a direct link between peroxisomal VLCFA accumulation (mediated by ABCD2 deficiency) and neuroinflammatory signaling.","method":"siRNA knockdown of Abcd1/Abcd2 in primary astrocytes, VLCFA measurement, inflammatory marker expression, transcription factor activity assays","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA KD with functional inflammatory readout and transcription factor analysis, single lab","pmids":["18723473"],"is_preprint":false},{"year":2009,"finding":"TRβ-selective thyromimetics (GC-1, CGS 23425) induce ABCD2 expression dose-dependently via the ABCD2 promoter thyroid hormone response element, and maintain prolonged induction (up to 10 days) in X-ALD fibroblasts compared to T3 alone, demonstrating that the TRβ pathway can be selectively targeted for sustained ABCD2 upregulation.","method":"Reporter gene assay, RT-qPCR in HepG2 cells and X-ALD fibroblasts, dose-response with selective TRβ agonists","journal":"The Journal of steroid biochemistry and molecular biology","confidence":"Medium","confidence_rationale":"Tier 3 — pharmacological induction with reporter and expression assays, single lab","pmids":["19406244"],"is_preprint":false},{"year":2010,"finding":"ABCD2 is highly abundant in adipose tissue (>50-fold higher than brain/adrenal) and is upregulated during adipogenesis. In Abcd2-knockout mice, adipose tissue accumulates 20:1 and 22:1 fatty acids, and dietary erucic acid (C22:1) accumulates in adipose in a gene-dosage-dependent manner, demonstrating that ABCD2 opposes accumulation of monounsaturated very-long-chain fatty acids in fat.","method":"Immunoblotting (quantitative), adipogenesis assay in D2-deficient MEFs, dietary erucic acid challenge with fatty acid profiling in knockout mice","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic knockout with dietary challenge and quantitative fatty acid profiling, multiple orthogonal methods","pmids":["19556607"],"is_preprint":false},{"year":2010,"finding":"Human ABCD1 and ABCD2 can both function as homodimers when expressed in pxa1/pxa2Δ yeast lacking peroxisomal fatty acid import. They have distinct substrate specificities: ABCD2 rescues β-oxidation best with C22:0, C24:6, and especially C22:6 (DHA), while ABCD1 rescues best with C24:0 and C26:0, demonstrating differential substrate specificity between the two paralogs.","method":"Functional complementation of S. cerevisiae pxa1/pxa2Δ mutant with human ABCD1 or ABCD2, β-oxidation assays with specific radiolabeled fatty acid substrates, growth assays on oleate","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1-2 — yeast reconstitution system with multiple specific substrates, directly demonstrates substrate specificity differences","pmids":["21145416"],"is_preprint":false},{"year":2011,"finding":"ABCD2 (ALDRP) physically interacts with ABCD1 (ALDP): proximity ligation assays and co-immunoprecipitation demonstrate a direct physical interaction. Expression of a non-functional ALDRP-EGFP fusion exerts a transdominant-negative effect on ABCD1 function. ABCD2 has redundant substrate activity for saturated VLCFA (C26:0, C24:0) and monounsaturated VLCFA, but a specific role in DHA (C22:6n-3) metabolism.","method":"Proximity ligation assay, co-immunoprecipitation, inducible dose-dependent expression of wild-type vs. mutant ALDRP-EGFP, fatty acid profiling in phospholipids, β-oxidation assays with C26:0, C24:0, and DHA","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal interaction evidence (PLA + CoIP) combined with functional epistasis (transdominant negative) and substrate-specific β-oxidation assays","pmids":["21209459"],"is_preprint":false},{"year":2013,"finding":"ABCD2 is a direct transcriptional target of the β-catenin/TCF-4 (Wnt signaling) pathway. Two functional TCF-4 binding elements were identified in the ABCD2 promoter (positions -360 to -260); mutation of either or both reduced promoter activity. Chromatin immunoprecipitation confirmed direct β-catenin binding to the ABCD2 promoter. Ectopic β-catenin/TCF-4 expression increased ABCD2 mRNA and reduced VLCFA levels.","method":"In silico promoter analysis, luciferase reporter assays, site-directed mutagenesis, chromatin immunoprecipitation (ChIP), RT-PCR, VLCFA measurement","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus mutagenesis plus functional VLCFA rescue, multiple orthogonal methods","pmids":["23437103"],"is_preprint":false},{"year":2014,"finding":"Abcd2 acts as a strong modifier of VLCFA metabolism in peritoneal macrophages: Abcd1/Abcd2 double-deficient macrophages accumulate VLCFA ~6-fold compared to wild-type (vs. ~2-fold for Abcd1-single deficiency), and show peroxisomal β-oxidation reduced to 29% of wild-type (vs. 62% for Abcd1-single deficiency). Single Abcd2 deficiency alone does not compromise β-oxidation of C26:0, demonstrating ABCD2 functions as a compensatory transporter for VLCFA import in macrophages.","method":"Thioglycollate-elicited peritoneal macrophages from single and double knockout mice, GC-MS VLCFA quantification, peroxisomal β-oxidation assay, RT-PCR","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — comparative single/double knockout with quantitative biochemical assays, multiple genotypes tested","pmids":["25255441"],"is_preprint":false},{"year":2014,"finding":"ABCD2 localizes to a distinct subclass of microperoxisomes (~200 nm) in mouse adipose tissue that lack classical peroxisome markers (catalase, PEX19, ABCD3). Immunoisolation and proteomic profiling of D2-containing organelles revealed associated proteins from peroxisome, ER, and mitochondria, suggesting physical association of this ABCD2-containing compartment with mitochondria and ER.","method":"Subcellular fractionation, electron microscopy, immunoisolation, proteomics/mass spectrometry, immunofluorescence with PEX19 and D2 antibodies","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — multiple localization methods plus proteomics, single lab","pmids":["25446110"],"is_preprint":false},{"year":2014,"finding":"LXR antagonists (GSK17, 22S-hydroxycholesterol) induce ABCD2 expression in human hepatoma cells and X-ALD fibroblasts, accompanied by decreased oxidative stress. In vivo, 22S-HC treatment of rats induces hepatic Abcd2. This confirms that LXR acts as a repressor of ABCD2 and that its antagonism can upregulate ABCD2 expression with functional consequences.","method":"Cell treatment with LXR antagonists/agonists, RT-PCR, oxidative stress assays, in vivo rat treatment, multiple tissue expression array","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 3 — pharmacological perturbation in vitro and in vivo, single lab, consistent with prior mechanistic work on LXRα","pmids":["24239766"],"is_preprint":false},{"year":2014,"finding":"ABCD2 modulates PPARα signaling: D2-deficient mice show altered gene expression clusters associated with lipid metabolism including PPARα signaling. Knockdown of D2 in 3T3-L1 adipocytes (which express high D2 levels) modifies genomic responses to fibrate treatment, though these effects are not sufficient to alter fibrate effects on diet-induced obesity phenotypes in vivo.","method":"D2-knockout mice with fenofibrate treatment, gene expression profiling, siRNA knockdown in 3T3-L1 adipocytes, dietary obesity model","journal":"Molecular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo knockout plus cell knockdown with genome-wide expression, single lab","pmids":["25123288"],"is_preprint":false},{"year":2016,"finding":"ABCD2 upregulation by metformin is dependent on AMPKα1: metformin activates AMPKα1 in X-ALD fibroblasts and induces ABCD2 protein levels in vitro and in vivo (brain and spinal cord of Abcd1-KO mice). Metformin-induced ABCD2 induction is abrogated in AMPKα1-KO mouse primary glial cells, establishing AMPKα1 as a required mediator of metformin-induced ABCD2 expression.","method":"Pharmacological AMPK activation, AMPKα1-knockout mouse glial cells, western blotting, in vivo metformin treatment, VLCFA measurement","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO (AMPKα1) combined with pharmacological rescue in vitro and in vivo, single lab","pmids":["26849413"],"is_preprint":false},{"year":2018,"finding":"ABCD2 knockdown in human OA chondrocytes causes VLCFA accumulation, apoptotic cell death, altered miRNA profiles, and decreased ACSL4 expression. The regulatory network ABCD2→miR-141→ACSL4 serves as a novel regulator of cartilage lipid homeostasis, and ACSL4 loss promotes MMP-13 expression and cartilage degradation.","method":"ABCD2 siRNA knockdown in human chondrocytes, VLCFA profiling, miRNA array, ACSL4 knockdown (in vitro and in vivo in mouse OA model), zebrafish morpholino knockdown of ACSL4 homolog","journal":"Cell biochemistry and function","confidence":"Medium","confidence_rationale":"Tier 3 — siRNA KD with downstream pathway analysis, in vivo validation in zebrafish and mouse models, single lab","pmids":["30264402"],"is_preprint":false},{"year":2019,"finding":"CRISPR/Cas9-mediated double knockout of Abcd1 and Abcd2 in BV-2 microglial cells results in VLCFA accumulation and lipid inclusions similar to brain macrophages of X-ALD patients. Single Abcd2 knockout alone does not cause VLCFA accumulation, while double deficiency markedly increases cholesterol and neutral lipids and alters expression of microglial function genes (Trem2), demonstrating functional redundancy in microglia.","method":"CRISPR/Cas9 double knockout in murine BV-2 microglia, electron microscopy, lipid profiling (cholesterol, neutral lipids, VLCFA), RT-PCR for microglial gene expression","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPR KO with multiple lipid and ultrastructural phenotypic readouts, single lab","pmids":["30769094"],"is_preprint":false},{"year":2025,"finding":"ABCD2 participates in an ABCD2/PEX2/ATGL axis regulating hepatocellular fatty acid metabolic reprogramming in MASLD. Gene overexpression validated that the herbal formula JTTZF downregulates peroxisomal ABCD2, and ABCD2 overexpression independently reduces lipid droplets and ROS in oleic/palmitic acid-treated HepG2 cells.","method":"Multi-omics (transcriptomics, proteomics) in HFD mouse model, ABCD2 overexpression in HepG2 cells, ROS flow cytometry, DHE staining, western blotting, immunohistochemistry","journal":"Phytomedicine","confidence":"Low","confidence_rationale":"Tier 3 — single lab, ABCD2 axis proposed from multi-omics with overexpression validation but limited mechanistic dissection of the axis","pmids":["40674914"],"is_preprint":false}],"current_model":"ABCD2 is a peroxisomal half-ABC transporter that functions as a homodimer (and can heterodimerize with ABCD1) to transport CoA-esters of very long-chain and polyunsaturated fatty acids (particularly DHA/C22:6 and saturated VLCFA) across the peroxisomal membrane for β-oxidation; it is transcriptionally regulated by multiple pathways including SREBP/SRE, LXRα (repressor), PPARα, TRα/TRβ via overlapping SRE/DR-4 elements, β-catenin/TCF-4, and AMPKα1-dependent signaling, and functionally overlaps with ABCD1 in preventing VLCFA accumulation and neurodegeneration, while retaining a specific non-redundant role in DHA metabolism, adrenal oxidative homeostasis, adipose lipid handling, and cartilage lipid regulation."},"narrative":{"teleology":[{"year":1997,"claim":"Cloning of ABCD2 established it as a peroxisomal half-ABC transporter paralog of ABCD1, raising the question of whether it could compensate for ABCD1 loss in X-ALD.","evidence":"cDNA cloning and sequence analysis showing 62.8% identity to ABCD1, tissue expression profiling","pmids":["9345306"],"confidence":"Medium","gaps":["No functional activity demonstrated","Dimerization predicted but not tested","Peroxisomal localization not directly confirmed"]},{"year":1999,"claim":"Direct localization to peroxisomes and functional complementation of VLCFA oxidation in ABCD1-deficient cells demonstrated that ABCD2 could substitute for ABCD1, answering the functional redundancy question at the cellular level.","evidence":"Subcellular fractionation, immunolocalization, and VLCFA oxidation rescue in X-ALD fibroblasts","pmids":["10329405"],"confidence":"Medium","gaps":["Substrate specificity unknown","In vivo redundancy not tested","Single lab observation"]},{"year":2002,"claim":"Identification of a functional SRE in the ABCD2 promoter revealed that sterol depletion via SREBP activates ABCD2 transcription, providing the first defined transcriptional regulatory mechanism and a pharmacological route to upregulate ABCD2 in X-ALD cells.","evidence":"Reporter assays, site-directed mutagenesis, EMSA, and VLCFA reduction in X-ALD fibroblasts upon sterol depletion","pmids":["12374760"],"confidence":"High","gaps":["Whether SREBP-mediated induction is sufficient in vivo to rescue disease unknown","Contribution of other transcription factors at overlapping elements not yet mapped"]},{"year":2003,"claim":"Discovery that thyroid hormone induces ABCD2 via TRβ binding to a promoter response element—with functional VLCFA normalization in ABCD1-deficient cells—established a second major transcriptional axis and raised the possibility of thyromimetic therapy.","evidence":"EMSA (RXR/TRβ binding), TRβ-knockout mice, cell-type specific induction in oligodendrocytes, β-oxidation assay in X-ALD fibroblasts","pmids":["12761339"],"confidence":"High","gaps":["Whether CNS-relevant cell types respond sufficiently in vivo unknown","TRα versus TRβ contributions not fully dissected"]},{"year":2004,"claim":"In vivo genetic epistasis using transgenic ABCD2 overexpression and Abcd1/Abcd2 double knockouts proved functional redundancy at the organismal level: ABCD2 prevented VLCFA accumulation and neurodegeneration, while combined loss accelerated disease with inflammation.","evidence":"Transgenic ABCD2 overexpression in Abcd1-KO mice; Abcd1/Abcd2 double KO with histopathology and VLCFA measurement","pmids":["15489218"],"confidence":"High","gaps":["Degree of substrate overlap versus specificity not resolved","Mechanism of inflammatory exacerbation in double KO unclear"]},{"year":2005,"claim":"Characterization of Abcd2-knockout mice revealed a non-redundant role: ABCD2 loss alone causes late-onset cerebellar/sensory ataxia with Purkinje cell degeneration and organelle damage, while LXRα was identified as a repressor competing with SREBP at overlapping SRE/DR-4 promoter elements.","evidence":"Abcd2-KO mouse phenotyping with electron microscopy and VLCFA measurement; LXRα/β-KO mice, EMSA, and reporter assays for promoter regulation","pmids":["16223892","16249184"],"confidence":"High","gaps":["Molecular basis of organelle cross-talk damage unknown","Relative in vivo contributions of SREBP versus LXR to tissue-specific expression not quantified"]},{"year":2008,"claim":"Defining the overlapping TRα/TRβ/SREBP interplay at the SRE/DR-4 element, combined with substrate profiling in knockout brain slices, established that ABCD2 has distinct preferred substrates (C22:0, monounsaturated VLCFA, DHA precursors) and that its transcriptional control integrates thyroid hormone and sterol signals at a single regulatory module.","evidence":"TRα-KO and TRβ-KO mice with EMSA and reporter assays; radiolabeled β-oxidation assays and fatty acid profiling in Abcd2-KO brain slices and primary neurons","pmids":["18834645","18854420"],"confidence":"High","gaps":["Direct transport assay with purified protein not performed","Whether TR-SREBP interaction is direct or mediated by cofactors unknown"]},{"year":2010,"claim":"Yeast reconstitution definitively demonstrated that ABCD2 homodimers transport CoA-esters with specificity for C22:0, C24:6, and especially DHA (C22:6), distinct from ABCD1's preference for C24:0/C26:0, while adipose tissue studies revealed ABCD2 as the dominant peroxisomal transporter opposing monounsaturated VLCFA accumulation in fat.","evidence":"Functional complementation in S. cerevisiae pxa1/pxa2Δ with radiolabeled substrates; Abcd2-KO mice with dietary erucic acid challenge and quantitative fatty acid profiling in adipose","pmids":["21145416","19556607"],"confidence":"High","gaps":["No structural basis for substrate discrimination","Homodimer versus heterodimer substrate preferences not compared in the same system"]},{"year":2011,"claim":"Physical interaction between ABCD1 and ABCD2 was demonstrated by proximity ligation assay and co-immunoprecipitation, with a non-functional ABCD2 exerting a transdominant-negative effect on ABCD1, confirming heterodimer formation and its functional relevance.","evidence":"PLA, co-IP, inducible expression of WT versus mutant ABCD2-EGFP, fatty acid profiling, β-oxidation assays","pmids":["21209459"],"confidence":"High","gaps":["Stoichiometry and structural architecture of heterodimer unknown","Whether heterodimer has distinct substrate specificity from either homodimer not determined"]},{"year":2013,"claim":"Identification of β-catenin/TCF-4 as a direct transcriptional activator of ABCD2 via two promoter TCF-4 elements added a Wnt-responsive dimension to ABCD2 regulation, with functional VLCFA reduction upon ectopic β-catenin expression.","evidence":"ChIP confirming β-catenin binding, site-directed mutagenesis of TCF-4 elements, luciferase reporters, RT-PCR, VLCFA measurement","pmids":["23437103"],"confidence":"High","gaps":["Physiological context of Wnt-dependent ABCD2 regulation (which tissues, when) not established","Interplay with SREBP/LXR/TR at the same promoter region not tested"]},{"year":2016,"claim":"Metformin-induced ABCD2 upregulation was shown to require AMPKα1, as demonstrated by abrogation in AMPKα1-KO glial cells, establishing a metabolic-sensing kinase pathway for ABCD2 induction with potential therapeutic relevance for X-ALD.","evidence":"AMPKα1-KO mouse primary glial cells, metformin treatment in vitro and in vivo (Abcd1-KO mice), western blotting","pmids":["26849413"],"confidence":"Medium","gaps":["Direct mechanism linking AMPKα1 to ABCD2 promoter (which transcription factor is the effector) unknown","Single lab; in vivo VLCFA reduction by metformin not demonstrated"]},{"year":null,"claim":"No high-resolution structure of ABCD2 exists, the molecular basis for its substrate selectivity over ABCD1 is structurally undefined, and the relative physiological contributions of ABCD2 homodimers versus ABCD1–ABCD2 heterodimers remain uncharacterized in vivo.","evidence":"","pmids":[],"confidence":"High","gaps":["No cryo-EM or crystal structure of ABCD2","In vivo stoichiometry of homo- versus heterodimer pools in different tissues unknown","Whether ABCD2 transports substrates as CoA esters or free fatty acids in mammalian membranes not directly demonstrated with purified protein"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[9,17]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[1,6,12,17,18]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[12,16,17]}],"localization":[{"term_id":"GO:0005777","term_label":"peroxisome","supporting_discovery_ids":[0,1,21]}],"pathway":[{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[1,6,17,18]}],"complexes":["ABCD2 homodimer","ABCD1–ABCD2 heterodimer"],"partners":["ABCD1","SREBF1","NR1H3","THRB","THRA","CTNNB1","TCF7L2","PRKAA1"],"other_free_text":[]},"mechanistic_narrative":"ABCD2 is a peroxisomal half-ABC transporter that imports very long-chain and polyunsaturated fatty acid CoA-esters—particularly C22:6 (DHA), C22:0, and monounsaturated VLCFA—into peroxisomes for β-oxidation, functioning as a homodimer or heterodimer with ABCD1 [PMID:21145416, PMID:21209459]. ABCD2 is functionally redundant with ABCD1 for saturated VLCFA transport, as transgenic ABCD2 overexpression prevents VLCFA accumulation and neurodegeneration in Abcd1-knockout mice, while Abcd1/Abcd2 double knockout produces synergistically severe disease [PMID:15489218, PMID:25255441]. Loss of ABCD2 alone causes late-onset cerebellar and sensory ataxia with Purkinje cell loss, VLCFA accumulation, and mitochondrial/ER/Golgi damage, and uniquely disrupts adrenal oxidative homeostasis and adipose monounsaturated VLCFA clearance [PMID:16223892, PMID:17260006, PMID:19556607]. ABCD2 transcription is activated by SREBP via a promoter SRE element, by thyroid hormone receptors (TRα/TRβ) via an overlapping SRE/DR-4 motif, by β-catenin/TCF-4, and by AMPK α1-dependent signaling, while LXRα acts as a repressor competing at the same SRE/DR-4 site [PMID:12374760, PMID:18834645, PMID:16249184, PMID:23437103, PMID:26849413]."},"prefetch_data":{"uniprot":{"accession":"Q9UBJ2","full_name":"ATP-binding cassette sub-family D member 2","aliases":["Adrenoleukodystrophy-like 1","Adrenoleukodystrophy-related protein","hALDR"],"length_aa":740,"mass_kda":83.2,"function":"ATP-dependent transporter of the ATP-binding cassette (ABC) family involved in the transport of very long chain fatty acid (VLCFA)-CoA from the cytosol to the peroxisome lumen (PubMed:21145416, PubMed:29397936). Like ABCD1 seems to have fatty acyl-CoA thioesterase (ACOT) and ATPase activities, according to this model, VLCFA-CoA as free VLCFA is transpoted in an ATP-dependent manner into peroxisomes after the hydrolysis of VLCFA-CoA mediated by the ACOT activity of ABCD2 (Probable) (PubMed:29397936). Shows overlapping substrate specificities with ABCD1 toward saturated fatty acids (FA) and monounsaturated FA (MUFA) but has a distinct substrate preference for shorter VLCFA (C22:0) and polyunsaturated fatty acid (PUFA) such as C22:6-CoA and C24:6-CoA (in vitro) (PubMed:21145416). Thus, may play a role in regulation of VLCFAs and energy metabolism namely, in the degradation and biosynthesis of fatty acids by beta-oxidation (PubMed:21145416)","subcellular_location":"Peroxisome membrane","url":"https://www.uniprot.org/uniprotkb/Q9UBJ2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ABCD2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ABCD2","total_profiled":1310},"omim":[{"mim_id":"614362","title":"ACYL-CoA SYNTHETASE, BUBBLEGUM FAMILY, MEMBER 1; ACSBG1","url":"https://www.omim.org/entry/614362"},{"mim_id":"603214","title":"ATP-BINDING CASSETTE, SUBFAMILY D, MEMBER 4; ABCD4","url":"https://www.omim.org/entry/603214"},{"mim_id":"601081","title":"ATP-BINDING CASSETTE, SUBFAMILY 3, MEMBER 2; ABCD2","url":"https://www.omim.org/entry/601081"},{"mim_id":"300371","title":"ATP-BINDING CASSETTE, SUBFAMILY D, MEMBER 1; ABCD1","url":"https://www.omim.org/entry/300371"},{"mim_id":"300100","title":"ADRENOLEUKODYSTROPHY; ALD","url":"https://www.omim.org/entry/300100"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"adipose tissue","ntpm":14.8}],"url":"https://www.proteinatlas.org/search/ABCD2"},"hgnc":{"alias_symbol":["ALDR","ALDRP"],"prev_symbol":["ALDL1"]},"alphafold":{"accession":"Q9UBJ2","domains":[{"cath_id":"1.20.1560.10","chopping":"78-436","consensus_level":"medium","plddt":86.6187,"start":78,"end":436},{"cath_id":"3.40.50.300","chopping":"471-688","consensus_level":"high","plddt":91.4462,"start":471,"end":688},{"cath_id":"1.10.287","chopping":"697-739","consensus_level":"high","plddt":73.076,"start":697,"end":739}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UBJ2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UBJ2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UBJ2-F1-predicted_aligned_error_v6.png","plddt_mean":81.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ABCD2","jax_strain_url":"https://www.jax.org/strain/search?query=ABCD2"},"sequence":{"accession":"Q9UBJ2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UBJ2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UBJ2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UBJ2"}},"corpus_meta":[{"pmid":"15489218","id":"PMC_15489218","title":"Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy.","date":"2004","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15489218","citation_count":162,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21145416","id":"PMC_21145416","title":"Differential substrate specificities of human ABCD1 and ABCD2 in peroxisomal fatty acid β-oxidation.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21145416","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18854420","id":"PMC_18854420","title":"A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis.","date":"2008","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18854420","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16223892","id":"PMC_16223892","title":"Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to late-onset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16223892","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9345306","id":"PMC_9345306","title":"cDNA cloning and mRNA expression of the human adrenoleukodystrophy related protein (ALDRP), a peroxisomal ABC transporter.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9345306","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18723473","id":"PMC_18723473","title":"Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy.","date":"2008","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/18723473","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11422379","id":"PMC_11422379","title":"Fibrate induction of the adrenoleukodystrophy-related gene (ABCD2): promoter analysis and role of the peroxisome proliferator-activated receptor PPARalpha.","date":"2001","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11422379","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12374760","id":"PMC_12374760","title":"Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy.","date":"2002","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12374760","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30769094","id":"PMC_30769094","title":"CRISPR/Cas9-mediated knockout of Abcd1 and Abcd2 genes in BV-2 cells: novel microglial models for X-linked Adrenoleukodystrophy.","date":"2019","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/30769094","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21209459","id":"PMC_21209459","title":"Substrate specificity overlap and interaction between adrenoleukodystrophy protein (ALDP/ABCD1) and adrenoleukodystrophy-related protein (ALDRP/ABCD2).","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21209459","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16249184","id":"PMC_16249184","title":"Liver X receptor alpha interferes with SREBP1c-mediated Abcd2 expression. Novel cross-talk in gene regulation.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16249184","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12761339","id":"PMC_12761339","title":"Thyroid hormone induction of the adrenoleukodystrophy-related gene (ABCD2).","date":"2003","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12761339","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17260006","id":"PMC_17260006","title":"The role of peroxisomal ABC transporters in the mouse adrenal gland: the loss of Abcd2 (ALDR), Not Abcd1 (ALD), causes oxidative damage.","date":"2007","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17260006","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19406244","id":"PMC_19406244","title":"Induction of the adrenoleukodystrophy-related gene (ABCD2) by thyromimetics.","date":"2009","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19406244","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20661612","id":"PMC_20661612","title":"Identification of novel SNPs of ABCD1, ABCD2, ABCD3, and ABCD4 genes in patients with X-linked adrenoleukodystrophy (ALD) based on comprehensive resequencing and association studies with ALD phenotypes.","date":"2010","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/20661612","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19556607","id":"PMC_19556607","title":"ABCD2 is abundant in adipose tissue and opposes the accumulation of dietary erucic acid (C22:1) in fat.","date":"2010","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/19556607","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18834645","id":"PMC_18834645","title":"Distinct modulatory roles for thyroid hormone receptors TRalpha and TRbeta in SREBP1-activated ABCD2 expression.","date":"2008","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18834645","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18834860","id":"PMC_18834860","title":"X-linked adrenoleukodystrophy phenotype is independent of ABCD2 genotype.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18834860","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25255441","id":"PMC_25255441","title":"Abcd2 is a strong modifier of the metabolic impairments in peritoneal macrophages of ABCD1-deficient mice.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25255441","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21299488","id":"PMC_21299488","title":"Clinical predictive value of the ABCD2 score for early risk of stroke in patients who have had transient ischaemic attack and who present to an Australian tertiary hospital.","date":"2011","source":"The Medical journal of Australia","url":"https://pubmed.ncbi.nlm.nih.gov/21299488","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11087670","id":"PMC_11087670","title":"Characterization of the adrenoleukodystrophy-related (ALDR, ABCD2) gene promoter: inductibility by retinoic acid and forskolin.","date":"2000","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11087670","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23318275","id":"PMC_23318275","title":"Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1/2 silenced mouse primary astrocytes.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23318275","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19717021","id":"PMC_19717021","title":"D-dimer, magnetic resonance imaging diffusion-weighted imaging, and ABCD2 score for transient ischemic attack risk stratification.","date":"2009","source":"Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association","url":"https://pubmed.ncbi.nlm.nih.gov/19717021","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26849413","id":"PMC_26849413","title":"Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase.","date":"2016","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26849413","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10329405","id":"PMC_10329405","title":"Full length cDNA cloning, promoter sequence, and genomic organization of the human adrenoleukodystrophy related (ALDR) gene functionally redundant to the gene responsible for X-linked adrenoleukodystrophy.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10329405","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26195594","id":"PMC_26195594","title":"Regulation Mechanism of the ald Gene Encoding Alanine Dehydrogenase in Mycobacterium smegmatis and Mycobacterium tuberculosis by the Lrp/AsnC Family Regulator AldR.","date":"2015","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/26195594","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11342107","id":"PMC_11342107","title":"Rat adrenoleukodystrophy-related (ALDR) gene: full-length cDNA sequence and new insight in expression.","date":"2001","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11342107","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24556878","id":"PMC_24556878","title":"ALDR enhanced endothelial injury in hyperuricemia screened using SILAC.","date":"2014","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24556878","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30264402","id":"PMC_30264402","title":"Suppression of ABCD2 dysregulates lipid metabolism via dysregulation of miR-141:ACSL4 in human osteoarthritis.","date":"2018","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/30264402","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27006398","id":"PMC_27006398","title":"Crystal Structure of Mycobacterium tuberculosis H37Rv AldR (Rv2779c), a Regulator of the ald Gene: DNA BINDING AND IDENTIFICATION OF SMALL MOLECULE INHIBITORS.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27006398","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24480443","id":"PMC_24480443","title":"Regulation of the adrenoleukodystrophy-related gene (ABCD2): focus on oxysterols and LXR antagonists.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24480443","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24239766","id":"PMC_24239766","title":"LXR antagonists induce ABCD2 expression.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24239766","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23749971","id":"PMC_23749971","title":"Regulation of the ald gene encoding alanine dehydrogenase by AldR in Mycobacterium smegmatis.","date":"2013","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/23749971","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23437103","id":"PMC_23437103","title":"ABCD2 is a direct target of β-catenin and TCF-4: implications for X-linked adrenoleukodystrophy therapy.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23437103","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9887385","id":"PMC_9887385","title":"Exon organisation of the mouse gene encoding the Adrenoleukodystrophy related protein (ALDRP).","date":"1998","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/9887385","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17686565","id":"PMC_17686565","title":"Dehydroepiandrosterone up-regulates the Adrenoleukodystrophy-related gene (ABCD2) independently of PPARalpha in rodents.","date":"2007","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/17686565","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26681085","id":"PMC_26681085","title":"Whole exome sequencing analysis of ABCC8 and ABCD2 genes associating with clinical course of breast carcinoma.","date":"2015","source":"Physiological research","url":"https://pubmed.ncbi.nlm.nih.gov/26681085","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28409470","id":"PMC_28409470","title":"Flow Cytometric Analysis of the Expression Pattern of Peroxisomal Proteins, Abcd1, Abcd2, and Abcd3 in BV-2 Murine Microglial Cells.","date":"2017","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/28409470","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16946495","id":"PMC_16946495","title":"ATP-binding and -hydrolysis activities of ALDP (ABCD1) and ALDRP (ABCD2), human peroxisomal ABC proteins, overexpressed in Sf21 cells.","date":"2006","source":"Biological & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/16946495","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35261213","id":"PMC_35261213","title":"Synthetic role of miR-200b-3p, ABCD2 score, and carotid ultrasound in the prediction of cerebral infarction in patients with transient ischemic attack.","date":"2022","source":"Brain and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/35261213","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25123288","id":"PMC_25123288","title":"ABCD2 alters peroxisome proliferator-activated receptor α signaling in vitro, but does not impair responses to fenofibrate therapy in a mouse model of diet-induced obesity.","date":"2014","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25123288","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23194953","id":"PMC_23194953","title":"Varying uses of the ABCD2 scoring system in primary and secondary care: a qualitative study.","date":"2012","source":"BMJ open","url":"https://pubmed.ncbi.nlm.nih.gov/23194953","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25446110","id":"PMC_25446110","title":"ABCD2 identifies a subclass of peroxisomes in mouse adipose tissue.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25446110","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40674914","id":"PMC_40674914","title":"Jiangtang Tiaozhi formula ameliorates MASLD by regulating liver ABCD2/PEX2/ATGL axis-mediated fatty acid metabolic reprogramming.","date":"2025","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40674914","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25079382","id":"PMC_25079382","title":"Evaluation of retinoids for induction of the redundant gene ABCD2 as an alternative treatment option in X-linked adrenoleukodystrophy.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25079382","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35937714","id":"PMC_35937714","title":"Value of Serum Adiponectin Combined with ABCD2 in Predicting Cerebral Infarction Among Patients with Acute Isolated Vertigo.","date":"2022","source":"Neuropsychiatric disease and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/35937714","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36844629","id":"PMC_36844629","title":"Taxol‑resistant breast cancer cell‑derived exosome‑delivered miR‑187‑5p regulates the growth of breast cancer cells via ABCD2 and Wnt/β‑catenin signaling.","date":"2023","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/36844629","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15944327","id":"PMC_15944327","title":"Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15944327","citation_count":681,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9169480","id":"PMC_9169480","title":"The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9169480","citation_count":474,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12949249","id":"PMC_12949249","title":"Many chemokines including CCL20/MIP-3alpha display antimicrobial activity.","date":"2003","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/12949249","citation_count":379,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18224687","id":"PMC_18224687","title":"CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer.","date":"2008","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18224687","citation_count":317,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9430724","id":"PMC_9430724","title":"Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9430724","citation_count":305,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8702936","id":"PMC_8702936","title":"Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8702936","citation_count":267,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12485447","id":"PMC_12485447","title":"Increased CCR4 expression in cutaneous T cell lymphoma.","date":"2002","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/12485447","citation_count":224,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17703412","id":"PMC_17703412","title":"Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes.","date":"2007","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17703412","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16859899","id":"PMC_16859899","title":"Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases.","date":"2006","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/16859899","citation_count":222,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14767451","id":"PMC_14767451","title":"Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis.","date":"2004","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14767451","citation_count":212,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33664865","id":"PMC_33664865","title":"Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/33664865","citation_count":166,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15113590","id":"PMC_15113590","title":"Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis.","date":"2004","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/15113590","citation_count":156,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14747532","id":"PMC_14747532","title":"Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus.","date":"2004","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/14747532","citation_count":149,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17548604","id":"PMC_17548604","title":"Down-regulation of E-cadherin in human bronchial epithelial cells leads to epidermal growth factor receptor-dependent Th2 cell-promoting activity.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17548604","citation_count":146,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15813816","id":"PMC_15813816","title":"Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis.","date":"2005","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/15813816","citation_count":138,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27525438","id":"PMC_27525438","title":"Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27525438","citation_count":136,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10737800","id":"PMC_10737800","title":"Shotgun sequencing of the human transcriptome with ORF expressed sequence tags.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10737800","citation_count":135,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24628072","id":"PMC_24628072","title":"Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis.","date":"2014","source":"The Journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/24628072","citation_count":125,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10493829","id":"PMC_10493829","title":"Genome duplications and other features in 12 Mb of DNA sequence from human chromosome 16p and 16q.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10493829","citation_count":124,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28381538","id":"PMC_28381538","title":"Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation.","date":"2017","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28381538","citation_count":120,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15067078","id":"PMC_15067078","title":"Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15067078","citation_count":116,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29099057","id":"PMC_29099057","title":"The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29099057","citation_count":106,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22981793","id":"PMC_22981793","title":"Phenotypic characterization of lung macrophages in asthmatic patients: overexpression of CCL17.","date":"2012","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22981793","citation_count":103,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23224400","id":"PMC_23224400","title":"Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma.","date":"2012","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23224400","citation_count":94,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18266834","id":"PMC_18266834","title":"Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis.","date":"2008","source":"Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18266834","citation_count":93,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9521068","id":"PMC_9521068","title":"Identification of the CC chemokines TARC and macrophage inflammatory protein-1 beta as novel functional ligands for the CCR8 receptor.","date":"1998","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9521068","citation_count":91,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":26247,"output_tokens":6289,"usd":0.086538},"stage2":{"model":"claude-opus-4-6","input_tokens":9884,"output_tokens":2929,"usd":0.183968},"total_usd":0.597439,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":41870,"output_tokens":7554,"usd":0.11946},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11438,"output_tokens":3245,"usd":0.207473}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"ABCD2 (ALDRP) was identified as a peroxisomal membrane ABC half-transporter with 62.8% amino acid identity to ABCD1, predicted to function as a homodimer or heterodimer with other peroxisomal ABC transporters, and localized exclusively to peroxisomes.\",\n      \"method\": \"cDNA cloning, subcellular localization by direct experimental analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct peroxisomal localization established; single lab with molecular cloning and localization data\",\n      \"pmids\": [\"9345306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Human ABCD2 (ALDRP) is exclusively localized to peroxisomes, and its overexpression in ABCD1-deficient cells complements the VLCFA beta-oxidation defect.\",\n      \"method\": \"Subcellular fractionation, transfection rescue assay in X-ALD fibroblasts\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization plus functional rescue, single lab\",\n      \"pmids\": [\"10329405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The ABCD2 promoter has functional activity driven by a ~1.3 kb 5'-upstream region containing Sp1- and AP-2-binding sites but no TATA box; promoter activity is upregulated by 9-cis-retinoic acid and forskolin but not PPARalpha in transfection assays.\",\n      \"method\": \"Luciferase reporter transfection assay, promoter characterization\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter assay with multiple inducers tested; single lab\",\n      \"pmids\": [\"11087670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ABCD2 induction by fibrates (fenofibrate) is dependent on PPARalpha, as it is absent in PPARalpha knockout mice; however, no functional PPRE was identified in the ABCD2 promoter by gel-shift and transfection assays, suggesting an indirect PPARalpha-dependent mechanism.\",\n      \"method\": \"PPARalpha knockout mice, gel-shift assay, COS-7 cell transfection, promoter analysis\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic knockout combined with promoter assays and gel-shift; multiple orthogonal methods\",\n      \"pmids\": [\"11422379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ABCD2 expression is induced by sterol depletion via activation of sterol regulatory element-binding proteins (SREBPs); a functional sterol regulatory element (SRE) was identified in the proximal ABCD2 promoter by reporter gene studies, site-directed mutagenesis, and gel-shift assays. ABCD2 induction by sterol depletion reduced VLCFA accumulation in X-ALD fibroblasts.\",\n      \"method\": \"Real-time PCR, reporter gene assay, site-directed mutagenesis, gel-shift assay, VLCFA measurement in fibroblasts\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods including mutagenesis and functional rescue; strong mechanistic evidence\",\n      \"pmids\": [\"12374760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The ABCD2 promoter contains a functional thyroid hormone response element (TRE) that binds RXR/TRbeta heterodimer; T3 treatment induces ABCD2 expression in rat liver in a TRbeta-dependent manner and in differentiated CG4 oligodendrocytes, correlating with normalization of VLCFA beta-oxidation in ABCD1-deficient fibroblasts.\",\n      \"method\": \"Gel-shift assay, TRbeta knockout mice, RT-PCR, VLCFA beta-oxidation assay in fibroblasts and oligodendrocytes\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — TRbeta KO validation combined with gel-shift and functional beta-oxidation assay; multiple orthogonal methods\",\n      \"pmids\": [\"12761339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ABCD2 functionally overlaps with ABCD1 in vivo: overexpression of ABCD2 in ABCD1 knockout mice prevents VLCFA accumulation and neurodegenerative features, while ABCD1/ABCD2 double knockout mice show earlier onset and more severe disease than ABCD1 single knockouts, demonstrating functional redundancy between the two transporters.\",\n      \"method\": \"Transgenic overexpression in ABCD1 KO mice, double knockout mice, VLCFA quantification, neuropathological analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic epistasis with multiple genotypes and orthogonal readouts; replicated across models\",\n      \"pmids\": [\"15489218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ABCD2 knockout mice develop late-onset cerebellar and sensory ataxia with Purkinje cell loss and dorsal root ganglia degeneration associated with VLCFA accumulation; pathological mechanism involves mitochondrial, Golgi, and endoplasmic reticulum damage, indicating disturbed organelle cross-talk downstream of ABCD2 loss.\",\n      \"method\": \"ABCD2 knockout mouse generation, neuropathology, electron microscopy, VLCFA quantification, organelle morphology analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — comprehensive characterization of KO mouse with multiple cellular readouts and organelle analyses\",\n      \"pmids\": [\"16223892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"LXRalpha acts as a negative modulator of ABCD2 expression through a novel regulatory mechanism where SREBP and LXRalpha binding sites overlap in the Abcd2 promoter (SRE/DR-4); SREBP1c induces adipose Abcd2, while concurrent LXRalpha activation counteracts SREBP1c-mediated hepatic Abcd2 induction, as demonstrated in LXRalpha/beta-deficient mice.\",\n      \"method\": \"Fasting-refeeding and cholesterol loading experiments, LXRalpha/beta knockout mice, EMSA with nuclear extracts, reporter assays, RT-PCR\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic knockout mice combined with EMSA and promoter assays; multiple orthogonal methods\",\n      \"pmids\": [\"16249184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ABCD2 (ALDRP) exhibits ATP-binding activity with affinity for ADP but not ATP (in contrast to ABCD1 which binds both ADP and ATP), and ABCD1 displays ATPase activity in membrane fractions of Sf21 insect cells; these activities are lost upon detergent solubilization, suggesting membrane components are required.\",\n      \"method\": \"Baculovirus expression in Sf21 cells, ATP/ADP-agarose binding, ATPase activity assay, immunoelectron microscopy, subcellular fractionation\",\n      \"journal\": \"Biological & pharmaceutical bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical assay of nucleotide binding and ATPase in heterologous expression system; single lab\",\n      \"pmids\": [\"16946495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Loss of ABCD2 (but not ABCD1) in mice causes oxidative damage in the adrenal gland, specifically premature ceroid deposition (an end-product of oxidative damage) in adrenal medullary cells and increased mitochondrial manganese superoxide dismutase immunoreactivity, indicating ABCD2 plays a specific role in protecting adrenal cells from oxidative stress.\",\n      \"method\": \"ABCD2 and ABCD1 knockout mice, immunohistochemistry for oxidative stress markers, electron microscopy, ceroid quantification\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — comparative KO mouse analysis with multiple readouts; large sample sizes (n=20/27)\",\n      \"pmids\": [\"17260006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ABCD2 (Abcd2) induction by DHEA in rodent liver is independent of PPARalpha, as demonstrated by DHEA-S treatment in primary rat hepatocytes and in PPARalpha knockout mice, distinguishing the mechanism from fibrate-induced ABCD2 regulation.\",\n      \"method\": \"Primary rat hepatocyte culture, PPARalpha knockout mice, RT-PCR, DHEA-S treatment\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — PPARalpha KO genetic evidence plus in vitro assay; single lab\",\n      \"pmids\": [\"17686565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ABCD2 plays a role in degradation of long-chain saturated and omega9-monounsaturated fatty acids and in synthesis of docosahexaenoic acid (DHA); ABCD2 knockout mice show defective VLCFA beta-oxidation in brain slices using radiolabeled hexacosanoic acid and DHA precursor as substrates.\",\n      \"method\": \"ABCD2 knockout mouse fatty acid profiling, radiolabeled substrate beta-oxidation assay in brain slices ex vivo, gas chromatography\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct ex vivo beta-oxidation assay in KO tissue with multiple substrate specificity data\",\n      \"pmids\": [\"18854420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"siRNA-mediated silencing of both Abcd1 and Abcd2 in mouse primary astrocytes causes VLCFA accumulation and induces an NF-kappaB/AP-1/C/EBP-mediated inflammatory response characteristic of cerebral ALD, establishing a direct link between VLCFA accumulation and neuroinflammation.\",\n      \"method\": \"siRNA knockdown in primary astrocytes, VLCFA measurement, inflammatory cytokine and iNOS expression, transcription factor activity assays\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — combined siRNA KD with pathway analysis; single lab but multiple readouts\",\n      \"pmids\": [\"18723473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TRalpha and TRbeta differentially modulate SREBP1-dependent ABCD2 expression through overlapping SRE/DR-4 elements in the promoter: unliganded TRbeta represses ABCD2 independently of DNA binding, while T3-dependent activation requires TRalpha and intact SRE/DR-4 motifs; temporal regulation in mouse liver is consistent with TRalpha/TRbeta expression patterns in vivo.\",\n      \"method\": \"EMSA with nuclear extracts, TRalpha and TRbeta knockout mice, reporter assays, RT-PCR under manipulated T3 states\",\n      \"journal\": \"European journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — dual KO mouse models combined with EMSA and promoter assays; multiple orthogonal methods\",\n      \"pmids\": [\"18834645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TRbeta-selective thyromimetics (GC-1 and CGS 23425) induce ABCD2 expression via the thyroid hormone response element in its promoter in a dose-dependent manner, and sustain ABCD2 induction longer than T3 in X-ALD fibroblasts, establishing TRbeta as the functional receptor for thyromimetic-mediated ABCD2 regulation.\",\n      \"method\": \"Reporter gene assay, RT-qPCR in human HepG2 cells and X-ALD fibroblasts, TRbeta-selective ligand pharmacology\",\n      \"journal\": \"The Journal of steroid biochemistry and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter and expression assays; single lab with multiple cell types\",\n      \"pmids\": [\"19406244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ABCD1 and ABCD2 have distinct substrate specificities: in a yeast pxa1/pxa2 complementation system, ABCD2 preferentially rescues beta-oxidation of C22:0, C24:6, and C22:6 (DHA), while ABCD1 preferentially rescues beta-oxidation of C24:0 and C26:0; both can function as homodimers.\",\n      \"method\": \"Heterologous expression in S. cerevisiae pxa1/pxa2 double mutant, fatty acid beta-oxidation assay with radiolabeled substrates, growth complementation\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in yeast with multiple substrates; rigorous biochemical complementation assay\",\n      \"pmids\": [\"21145416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ABCD2 is highly abundant in adipose tissue (>50-fold more than brain or adrenal), upregulated during adipogenesis, and opposes accumulation of dietary erucic acid (C22:1) in adipose in a gene-dosage-dependent manner; ABCD2 is a SREBP target gene in adipocytes.\",\n      \"method\": \"ABCD2 KO mouse model, adipogenesis assay with MEFs, dietary erucic acid challenge, gas chromatography fatty acid profiling, immunoblotting\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with dietary challenge and dosage-dependent response; single lab\",\n      \"pmids\": [\"19556607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ABCD2 and ABCD1 physically interact (form heterodimers); overexpression of a non-functional ABCD2-EGFP mutant exerts a transdominant-negative effect on ABCD1 function, demonstrated by proximity ligation assay and co-immunoprecipitation. ABCD2 is involved in metabolism of saturated VLCFA (redundant with ABCD1) and specifically in DHA metabolism.\",\n      \"method\": \"Proximity ligation assay, co-immunoprecipitation, inducible expression of wild-type vs. ATPase-dead ABCD2-EGFP, beta-oxidation assays with C26:0, C24:0, and C22:6n-3, phospholipid fatty acid profiling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — physical interaction confirmed by two orthogonal methods (PLA + co-IP) plus functional beta-oxidation assays with mutagenesis; strong mechanistic evidence\",\n      \"pmids\": [\"21209459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ABCD2 is a direct transcriptional target of beta-catenin and TCF-4: two TCF-4 binding elements in the ABCD2 promoter (-360 to -260) mediate transcriptional activation, validated by site-directed mutagenesis and chromatin immunoprecipitation; beta-catenin/TCF-4 overexpression reduces VLCFA levels.\",\n      \"method\": \"Reporter gene assay, site-directed mutagenesis, chromatin immunoprecipitation, RT-PCR, VLCFA measurement\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP plus mutagenesis plus functional VLCFA readout; multiple orthogonal methods\",\n      \"pmids\": [\"23437103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In ABCD1/ABCD2 double-deficient peritoneal macrophages, VLCFA (C26:0) accumulation is sixfold greater and peroxisomal beta-oxidation is reduced to 29% of wild-type (vs. 62% in single ABCD1 KO), demonstrating ABCD2 provides compensatory VLCFA transport into peroxisomes in macrophages when ABCD1 is absent.\",\n      \"method\": \"Single and double KO mouse macrophages, gas chromatography-mass spectrometry VLCFA quantification, peroxisomal beta-oxidation assay, RT-PCR\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — comparative KO analysis with quantitative biochemical assays across four genotypes\",\n      \"pmids\": [\"25255441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LXR antagonists (GSK17 and 22S-hydroxycholesterol) induce ABCD2 expression in human hepatoma cells and X-ALD fibroblasts, with concomitant decrease in oxidative stress; 22S-HC treatment in rats induces hepatic Abcd2 in vivo, establishing LXR as a repressor of ABCD2 whose antagonism de-represses ABCD2.\",\n      \"method\": \"LXR antagonist treatment in cell lines and rats, RT-PCR, oxidative stress assays, multiple tissue expression array\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vitro and in vivo induction data; single lab with multiple cell/animal models\",\n      \"pmids\": [\"24239766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ABCD2 is localized to a distinct subclass of peroxisomes (microperoxisomes, ~200 nm diameter) in mouse adipose tissue that lack canonical peroxisome markers (catalase, PEX19, ABCD3); proteomic profiling of immunoisolated D2-containing compartments reveals association with ER and mitochondrial proteins.\",\n      \"method\": \"Subcellular fractionation, electron microscopy, immunoisolation, mass spectrometry proteomics, immunofluorescence\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization by EM and immunoisolation with proteomic validation; single lab\",\n      \"pmids\": [\"25446110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Metformin induces ABCD2 expression in X-ALD fibroblasts and in ABCD1 KO mouse brain/spinal cord in vivo via AMPKalpha1-dependent signaling; ABCD2 induction is abolished in AMPKalpha1 KO mouse-derived glial cells, establishing AMPKalpha1 as a required upstream regulator of ABCD2.\",\n      \"method\": \"Metformin treatment of X-ALD fibroblasts, AMPKalpha1 KO primary glial cells, in vivo metformin treatment of ABCD1 KO mice, western blotting, RT-PCR, VLCFA measurement\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — AMPKalpha1 KO genetic validation in vitro plus in vivo mouse data; single lab\",\n      \"pmids\": [\"26849413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ABCD2 knockdown in human OA chondrocytes causes VLCFA accumulation and apoptotic cell death, and alters miRNA profiles affecting ACSL4 expression; reduced ACSL4 leads to VLCFA accumulation, MMP-13 expression, and apoptosis, placing ABCD2 upstream of ACSL4 in a lipid metabolic pathway relevant to cartilage homeostasis.\",\n      \"method\": \"siRNA knockdown in human chondrocytes, miRNA profiling, VLCFA measurement, apoptosis assay, ACSL4 KD in chondrocytes, in vivo morpholino KD in zebrafish\",\n      \"journal\": \"Cell biochemistry and function\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional KD with pathway placement; multiple readouts but single lab\",\n      \"pmids\": [\"30264402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Only combined CRISPR/Cas9-mediated knockout of both Abcd1 and Abcd2 in BV-2 microglial cells results in VLCFA accumulation and lipid inclusions similar to X-ALD brain macrophages; single Abcd2 KO alone is insufficient, demonstrating functional redundancy between the two transporters in microglia.\",\n      \"method\": \"CRISPR/Cas9 double knockout in BV-2 cells, VLCFA measurement, electron microscopy, cholesterol and neutral lipid analysis, RT-PCR\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO with multiple biochemical readouts; single lab\",\n      \"pmids\": [\"30769094\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ABCD2 is a peroxisomal membrane ABC half-transporter that functions as a homodimer or heterodimer with ABCD1 to transport CoA-esters of very long-chain fatty acids (particularly C22:0, unsaturated VLCFAs, and DHA) into peroxisomes for beta-oxidation; it partially overlaps with but has distinct substrate specificity from ABCD1, physically interacts with ABCD1 (demonstrated by co-IP and proximity ligation), and is transcriptionally regulated by multiple nuclear receptors including PPARalpha, SREBPs (via an SRE in its promoter), TRbeta (via a TRE), LXRalpha (as a repressor), and beta-catenin/TCF-4, with upstream regulation also involving AMPKalpha1; loss of ABCD2 in mice causes VLCFA accumulation, oxidative damage, organelle cross-talk disruption, and late-onset neurodegeneration, while its overexpression rescues ABCD1 deficiency in vivo.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries from KEPT papers only.\n\n**Classification:**\n\nPapers about canonical ABCD2 (peroxisomal ABC transporter): KEEP — [1]-[19], [21]-[25], [27]-[29], [31]-[32], [34]-[36], [38]-[39], [41], [43]-[45], [47] from retrieved papers.\n\nEXCLUDE (alias collisions):\n- Papers [20], [23], [40], [42], [46] — \"ABCD2 score\" (clinical TIA risk score, not the gene)\n- Papers [26], [30], [33] — AldR in Mycobacterium (bacterial regulator, symbol collision)\n- Paper [28] — \"ALDR\" = aldose reductase in HUVECs (alias collision, not ABCD2)\n\nAdditional gene2pubmed papers: All clearly about CCL17/CCL22/CCR4/chemokines or unrelated genomics — EXCLUDE (alias/off-target contamination).\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"ABCD2 (ALDRP) encodes a 740-amino-acid peroxisomal membrane protein that is a half-ABC transporter with 62.8% identity to ABCD1 (ALDP), predicted to form homodimers or heterodimers with other peroxisomal ABC transporters. mRNA is expressed predominantly in brain and heart.\",\n      \"method\": \"cDNA cloning, sequence analysis, tissue expression profiling\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, cDNA cloning with sequence/expression analysis, no functional reconstitution\",\n      \"pmids\": [\"9345306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Human ABCD2 (ALDRP) localizes exclusively to peroxisomes. The gene spans 33 kb on chromosome 12q12, consists of 10 exons, and its promoter contains a novel motif conserved among peroxisomal ABC transporters. ALDRP transfection into X-ALD cells complements the VLCFA oxidation defect.\",\n      \"method\": \"Subcellular fractionation, immunolocalization, genomic sequencing, functional complementation in ABCD1-deficient cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — direct localization plus functional complementation in cell model, single lab\",\n      \"pmids\": [\"10329405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The ABCD2 promoter (1.3 kb of human and mouse 5'-upstream region) has functional promoter activity and is upregulated by 9-cis-retinoic acid and forskolin. No PPARα response element was detected in the promoter by transfection assays.\",\n      \"method\": \"Luciferase reporter assays, promoter deletion/transfection in cell lines\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — reporter assays with multiple inducers, single lab\",\n      \"pmids\": [\"11087670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Fibrate induction of ABCD2 is PPARα-dependent in vivo (absent in PPARα-knockout mice), but no functional PPRE motif could be identified in the ABCD2 promoter by gel-shift assay and transfection of COS-7 cells, indicating a non-canonical PPARα-dependent regulatory mechanism.\",\n      \"method\": \"PPARα knockout mice treated with fenofibrate, gel-shift assay, promoter transfection in COS-7 cells\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic knockout combined with in vitro promoter assays, single lab\",\n      \"pmids\": [\"11422379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ABCD2 is transcriptionally induced by sterol depletion via activation of sterol regulatory element-binding proteins (SREBPs). A functional sterol regulatory element (SRE) was identified in the proximal ABCD2 promoter by reporter gene studies, site-directed mutagenesis, and gel-shift assays. ABCD2 induction by sterol depletion significantly reduced VLCFA accumulation in X-ALD fibroblasts.\",\n      \"method\": \"Real-time PCR, reporter gene assays, site-directed mutagenesis, gel-shift assay (EMSA), functional VLCFA measurement in patient fibroblasts\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including mutagenesis, EMSA, and functional rescue in patient cells\",\n      \"pmids\": [\"12374760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ABCD2 is induced by thyroid hormone (T3) via TRβ. The ABCD2 promoter contains a functional thyroid hormone response element that binds RXR/TRβ heterodimer, mediating T3 responsiveness. T3 induces ABCD2 in liver of normal rats but not TRβ-knockout mice, and in differentiated oligodendrocytes (CG4 cells) but not astrocytes. T3 induction in ABCD1-deficient fibroblasts normalized VLCFA β-oxidation.\",\n      \"method\": \"Gel-shift assay (RXR/TRβ binding), TRβ-knockout mice, liver induction in vivo, cell-type specific induction, β-oxidation assay in ABCD1-deficient fibroblasts\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic knockout, multiple cell types, functional rescue, multiple orthogonal methods\",\n      \"pmids\": [\"12761339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ABCD2 functionally overlaps with ABCD1 in vivo: overexpression of ABCD2 in Abcd1-knockout mice prevents VLCFA accumulation and neurodegenerative pathology (axonal damage followed by myelin degeneration). Double Abcd1/Abcd2 knockout mice display earlier onset and more severe disease, including inflammatory reaction, demonstrating functional redundancy between the two transporters.\",\n      \"method\": \"Transgenic overexpression of ABCD2 in Abcd1-KO mice, Abcd1/Abcd2 double knockout generation, histopathology, VLCFA measurement\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic epistasis with multiple knockout and transgenic models, multiple phenotypic readouts\",\n      \"pmids\": [\"15489218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Abcd2-knockout mice develop late-onset cerebellar and sensory ataxia with loss of Purkinje cells and dorsal root ganglia degeneration, correlating with VLCFA accumulation in those cells. The underlying pathological mechanism involves mitochondrial, Golgi, and endoplasmic reticulum damage, demonstrating disturbed organelle cross-talk as a downstream consequence of ABCD2 loss.\",\n      \"method\": \"Abcd2-knockout mouse generation and characterization, histopathology, electron microscopy of organelles, VLCFA measurement\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — constitutive knockout with defined cellular and ultrastructural phenotype, replicated across tissue types\",\n      \"pmids\": [\"16223892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"LXRα acts as a negative modulator of Abcd2 expression by competing with SREBP1c at overlapping SRE/DR-4 binding sites in the Abcd2 promoter. SREBP1c induces adipose Abcd2, while concurrent LXRα activation suppresses hepatic Abcd2. LXRα/β-deficient mice show greatly elevated Abcd2 induction, confirming LXRα as a repressor.\",\n      \"method\": \"EMSA with nuclear extracts, LXRα/β-knockout mice, fasting-refeeding and cholesterol loading paradigms, cell culture reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo knockout plus in vitro EMSA and reporter assays, multiple orthogonal approaches\",\n      \"pmids\": [\"16249184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ABCD2 (ALDRP) expressed in Sf21 insect cells via baculovirus shows ATPase activity in membrane fractions and nucleotide-binding capacity. Unlike ABCD1 which binds both ADP and ATP, ABCD2 binds ADP but has negligible affinity for ATP, suggesting functional differences in nucleotide binding between the two paralogs.\",\n      \"method\": \"Baculovirus-mediated overexpression in Sf21 cells, ATPase activity assay, ATP/ADP-agarose binding, immunoelectron microscopy, subcellular fractionation\",\n      \"journal\": \"Biological & pharmaceutical bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical activity assay in overexpression system, single lab\",\n      \"pmids\": [\"16946495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Loss of Abcd2 (not Abcd1) causes oxidative damage in the mouse adrenal gland: Abcd2 knockout mice show increased mitochondrial manganese superoxide dismutase immunoreactivity and spontaneous premature ceroid deposition (a marker of oxidative damage) predominantly in adrenal medullary cells, indicating a specific role for ABCD2 in limiting oxidative stress in adrenal tissue.\",\n      \"method\": \"Abcd1 and Abcd2 single/double knockout mice, immunohistochemistry for oxidative stress markers (MnSOD, ceroid), comparative genotype analysis\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — comparative knockout analysis with defined cellular phenotype, single lab\",\n      \"pmids\": [\"17260006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"DHEA induces Abcd2 and Abcd3 expression in rodent liver in vivo and in primary rat hepatocytes in vitro, but this induction of Abcd2 is independent of PPARα (unlike Abcd3), revealing a PPARα-independent pathway for ABCD2 regulation.\",\n      \"method\": \"In vivo DHEA treatment, primary hepatocyte cultures, PPARα-knockout mice comparison, RT-PCR\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro with PPARα-null comparison, single lab\",\n      \"pmids\": [\"17686565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ABCD2 plays a role in degradation of long-chain saturated and omega-9 monounsaturated fatty acids and in the synthesis of docosahexaenoic acid (DHA). Abcd2-knockout mouse brain slices show defective VLCFA β-oxidation ex vivo using radiolabeled hexacosanoic acid and DHA precursor, distinct from the substrate profile of Abcd1-knockout.\",\n      \"method\": \"Fatty acid profiling in knockout mouse organs and primary neurons, radiolabeled β-oxidation assay in brain slices, dietary challenge experiments\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (profiling + functional β-oxidation with radiolabeled substrates) in knockout models\",\n      \"pmids\": [\"18854420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TRα and TRβ bind the overlapping SRE/DR-4 motif in the ABCD2 promoter and differentially modulate SREBP1-dependent ABCD2 activation: unliganded TRβ (but not TRα) represses ABCD2 independently of DNA binding, while T3-dependent activation requires TRα and intact SRE/DR-4 motifs. EMSA with nuclear extracts supports direct TR-SREBP1 interaction at this element.\",\n      \"method\": \"EMSA, TRα and TRβ knockout mice, T3 manipulation (fasting/refeeding), reporter gene assays, RT-PCR in liver\",\n      \"journal\": \"European journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple receptor knockout mouse models plus EMSA and reporter assays\",\n      \"pmids\": [\"18834645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Silencing of Abcd1 and Abcd2 by siRNA in mouse primary astrocytes causes VLCFA accumulation and induces an inflammatory response (iNOS, inflammatory cytokines) mediated by NF-κB, AP-1, and C/EBP transcription factors, establishing a direct link between peroxisomal VLCFA accumulation (mediated by ABCD2 deficiency) and neuroinflammatory signaling.\",\n      \"method\": \"siRNA knockdown of Abcd1/Abcd2 in primary astrocytes, VLCFA measurement, inflammatory marker expression, transcription factor activity assays\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA KD with functional inflammatory readout and transcription factor analysis, single lab\",\n      \"pmids\": [\"18723473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TRβ-selective thyromimetics (GC-1, CGS 23425) induce ABCD2 expression dose-dependently via the ABCD2 promoter thyroid hormone response element, and maintain prolonged induction (up to 10 days) in X-ALD fibroblasts compared to T3 alone, demonstrating that the TRβ pathway can be selectively targeted for sustained ABCD2 upregulation.\",\n      \"method\": \"Reporter gene assay, RT-qPCR in HepG2 cells and X-ALD fibroblasts, dose-response with selective TRβ agonists\",\n      \"journal\": \"The Journal of steroid biochemistry and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological induction with reporter and expression assays, single lab\",\n      \"pmids\": [\"19406244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ABCD2 is highly abundant in adipose tissue (>50-fold higher than brain/adrenal) and is upregulated during adipogenesis. In Abcd2-knockout mice, adipose tissue accumulates 20:1 and 22:1 fatty acids, and dietary erucic acid (C22:1) accumulates in adipose in a gene-dosage-dependent manner, demonstrating that ABCD2 opposes accumulation of monounsaturated very-long-chain fatty acids in fat.\",\n      \"method\": \"Immunoblotting (quantitative), adipogenesis assay in D2-deficient MEFs, dietary erucic acid challenge with fatty acid profiling in knockout mice\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic knockout with dietary challenge and quantitative fatty acid profiling, multiple orthogonal methods\",\n      \"pmids\": [\"19556607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Human ABCD1 and ABCD2 can both function as homodimers when expressed in pxa1/pxa2Δ yeast lacking peroxisomal fatty acid import. They have distinct substrate specificities: ABCD2 rescues β-oxidation best with C22:0, C24:6, and especially C22:6 (DHA), while ABCD1 rescues best with C24:0 and C26:0, demonstrating differential substrate specificity between the two paralogs.\",\n      \"method\": \"Functional complementation of S. cerevisiae pxa1/pxa2Δ mutant with human ABCD1 or ABCD2, β-oxidation assays with specific radiolabeled fatty acid substrates, growth assays on oleate\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — yeast reconstitution system with multiple specific substrates, directly demonstrates substrate specificity differences\",\n      \"pmids\": [\"21145416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ABCD2 (ALDRP) physically interacts with ABCD1 (ALDP): proximity ligation assays and co-immunoprecipitation demonstrate a direct physical interaction. Expression of a non-functional ALDRP-EGFP fusion exerts a transdominant-negative effect on ABCD1 function. ABCD2 has redundant substrate activity for saturated VLCFA (C26:0, C24:0) and monounsaturated VLCFA, but a specific role in DHA (C22:6n-3) metabolism.\",\n      \"method\": \"Proximity ligation assay, co-immunoprecipitation, inducible dose-dependent expression of wild-type vs. mutant ALDRP-EGFP, fatty acid profiling in phospholipids, β-oxidation assays with C26:0, C24:0, and DHA\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal interaction evidence (PLA + CoIP) combined with functional epistasis (transdominant negative) and substrate-specific β-oxidation assays\",\n      \"pmids\": [\"21209459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ABCD2 is a direct transcriptional target of the β-catenin/TCF-4 (Wnt signaling) pathway. Two functional TCF-4 binding elements were identified in the ABCD2 promoter (positions -360 to -260); mutation of either or both reduced promoter activity. Chromatin immunoprecipitation confirmed direct β-catenin binding to the ABCD2 promoter. Ectopic β-catenin/TCF-4 expression increased ABCD2 mRNA and reduced VLCFA levels.\",\n      \"method\": \"In silico promoter analysis, luciferase reporter assays, site-directed mutagenesis, chromatin immunoprecipitation (ChIP), RT-PCR, VLCFA measurement\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus mutagenesis plus functional VLCFA rescue, multiple orthogonal methods\",\n      \"pmids\": [\"23437103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Abcd2 acts as a strong modifier of VLCFA metabolism in peritoneal macrophages: Abcd1/Abcd2 double-deficient macrophages accumulate VLCFA ~6-fold compared to wild-type (vs. ~2-fold for Abcd1-single deficiency), and show peroxisomal β-oxidation reduced to 29% of wild-type (vs. 62% for Abcd1-single deficiency). Single Abcd2 deficiency alone does not compromise β-oxidation of C26:0, demonstrating ABCD2 functions as a compensatory transporter for VLCFA import in macrophages.\",\n      \"method\": \"Thioglycollate-elicited peritoneal macrophages from single and double knockout mice, GC-MS VLCFA quantification, peroxisomal β-oxidation assay, RT-PCR\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — comparative single/double knockout with quantitative biochemical assays, multiple genotypes tested\",\n      \"pmids\": [\"25255441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ABCD2 localizes to a distinct subclass of microperoxisomes (~200 nm) in mouse adipose tissue that lack classical peroxisome markers (catalase, PEX19, ABCD3). Immunoisolation and proteomic profiling of D2-containing organelles revealed associated proteins from peroxisome, ER, and mitochondria, suggesting physical association of this ABCD2-containing compartment with mitochondria and ER.\",\n      \"method\": \"Subcellular fractionation, electron microscopy, immunoisolation, proteomics/mass spectrometry, immunofluorescence with PEX19 and D2 antibodies\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple localization methods plus proteomics, single lab\",\n      \"pmids\": [\"25446110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LXR antagonists (GSK17, 22S-hydroxycholesterol) induce ABCD2 expression in human hepatoma cells and X-ALD fibroblasts, accompanied by decreased oxidative stress. In vivo, 22S-HC treatment of rats induces hepatic Abcd2. This confirms that LXR acts as a repressor of ABCD2 and that its antagonism can upregulate ABCD2 expression with functional consequences.\",\n      \"method\": \"Cell treatment with LXR antagonists/agonists, RT-PCR, oxidative stress assays, in vivo rat treatment, multiple tissue expression array\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological perturbation in vitro and in vivo, single lab, consistent with prior mechanistic work on LXRα\",\n      \"pmids\": [\"24239766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ABCD2 modulates PPARα signaling: D2-deficient mice show altered gene expression clusters associated with lipid metabolism including PPARα signaling. Knockdown of D2 in 3T3-L1 adipocytes (which express high D2 levels) modifies genomic responses to fibrate treatment, though these effects are not sufficient to alter fibrate effects on diet-induced obesity phenotypes in vivo.\",\n      \"method\": \"D2-knockout mice with fenofibrate treatment, gene expression profiling, siRNA knockdown in 3T3-L1 adipocytes, dietary obesity model\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo knockout plus cell knockdown with genome-wide expression, single lab\",\n      \"pmids\": [\"25123288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ABCD2 upregulation by metformin is dependent on AMPKα1: metformin activates AMPKα1 in X-ALD fibroblasts and induces ABCD2 protein levels in vitro and in vivo (brain and spinal cord of Abcd1-KO mice). Metformin-induced ABCD2 induction is abrogated in AMPKα1-KO mouse primary glial cells, establishing AMPKα1 as a required mediator of metformin-induced ABCD2 expression.\",\n      \"method\": \"Pharmacological AMPK activation, AMPKα1-knockout mouse glial cells, western blotting, in vivo metformin treatment, VLCFA measurement\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO (AMPKα1) combined with pharmacological rescue in vitro and in vivo, single lab\",\n      \"pmids\": [\"26849413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ABCD2 knockdown in human OA chondrocytes causes VLCFA accumulation, apoptotic cell death, altered miRNA profiles, and decreased ACSL4 expression. The regulatory network ABCD2→miR-141→ACSL4 serves as a novel regulator of cartilage lipid homeostasis, and ACSL4 loss promotes MMP-13 expression and cartilage degradation.\",\n      \"method\": \"ABCD2 siRNA knockdown in human chondrocytes, VLCFA profiling, miRNA array, ACSL4 knockdown (in vitro and in vivo in mouse OA model), zebrafish morpholino knockdown of ACSL4 homolog\",\n      \"journal\": \"Cell biochemistry and function\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — siRNA KD with downstream pathway analysis, in vivo validation in zebrafish and mouse models, single lab\",\n      \"pmids\": [\"30264402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CRISPR/Cas9-mediated double knockout of Abcd1 and Abcd2 in BV-2 microglial cells results in VLCFA accumulation and lipid inclusions similar to brain macrophages of X-ALD patients. Single Abcd2 knockout alone does not cause VLCFA accumulation, while double deficiency markedly increases cholesterol and neutral lipids and alters expression of microglial function genes (Trem2), demonstrating functional redundancy in microglia.\",\n      \"method\": \"CRISPR/Cas9 double knockout in murine BV-2 microglia, electron microscopy, lipid profiling (cholesterol, neutral lipids, VLCFA), RT-PCR for microglial gene expression\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO with multiple lipid and ultrastructural phenotypic readouts, single lab\",\n      \"pmids\": [\"30769094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ABCD2 participates in an ABCD2/PEX2/ATGL axis regulating hepatocellular fatty acid metabolic reprogramming in MASLD. Gene overexpression validated that the herbal formula JTTZF downregulates peroxisomal ABCD2, and ABCD2 overexpression independently reduces lipid droplets and ROS in oleic/palmitic acid-treated HepG2 cells.\",\n      \"method\": \"Multi-omics (transcriptomics, proteomics) in HFD mouse model, ABCD2 overexpression in HepG2 cells, ROS flow cytometry, DHE staining, western blotting, immunohistochemistry\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, ABCD2 axis proposed from multi-omics with overexpression validation but limited mechanistic dissection of the axis\",\n      \"pmids\": [\"40674914\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ABCD2 is a peroxisomal half-ABC transporter that functions as a homodimer (and can heterodimerize with ABCD1) to transport CoA-esters of very long-chain and polyunsaturated fatty acids (particularly DHA/C22:6 and saturated VLCFA) across the peroxisomal membrane for β-oxidation; it is transcriptionally regulated by multiple pathways including SREBP/SRE, LXRα (repressor), PPARα, TRα/TRβ via overlapping SRE/DR-4 elements, β-catenin/TCF-4, and AMPKα1-dependent signaling, and functionally overlaps with ABCD1 in preventing VLCFA accumulation and neurodegeneration, while retaining a specific non-redundant role in DHA metabolism, adrenal oxidative homeostasis, adipose lipid handling, and cartilage lipid regulation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ABCD2 is a peroxisomal membrane ABC half-transporter that imports CoA-esters of very long-chain fatty acids—preferentially C22:0, C22:6 (DHA), and C24:6—into peroxisomes for β-oxidation, functioning as a homodimer or as a heterodimer with ABCD1 [PMID:21145416, PMID:21209459]. ABCD2 is partially redundant with ABCD1: its overexpression rescues VLCFA accumulation and neurodegeneration in ABCD1-deficient mice, while combined loss of both transporters produces synergistically severe phenotypes including VLCFA-driven neuroinflammation [PMID:15489218, PMID:25255441, PMID:30769094]. Loss of ABCD2 alone in mice causes late-onset cerebellar and sensory ataxia with Purkinje cell degeneration, VLCFA accumulation, oxidative damage, and disrupted organelle integrity in neurons and adrenal cells [PMID:16223892, PMID:17260006]. ABCD2 transcription is activated by SREBP (via a promoter SRE), thyroid hormone receptors (via a TRE), and β-catenin/TCF-4, and is repressed by LXRα through an overlapping SRE/DR-4 element, with upstream signaling through AMPKα1 [PMID:12374760, PMID:12761339, PMID:16249184, PMID:23437103, PMID:26849413].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Identification of ABCD2 as a peroxisomal ABC half-transporter with high homology to ABCD1 established a candidate redundant pathway for peroxisomal VLCFA import.\",\n      \"evidence\": \"cDNA cloning and subcellular localization in human cells\",\n      \"pmids\": [\"9345306\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional transport data; localization based on single lab\", \"Dimerization state inferred from homology, not demonstrated\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstration that ABCD2 overexpression rescues VLCFA β-oxidation in ABCD1-deficient fibroblasts established functional overlap between the two transporters.\",\n      \"evidence\": \"Transfection rescue assay in X-ALD patient fibroblasts with subcellular fractionation\",\n      \"pmids\": [\"10329405\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vivo evidence of rescue at this stage\", \"Substrate specificity differences between ABCD1 and ABCD2 not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of a functional SRE in the ABCD2 promoter revealed SREBP-dependent transcriptional control and connected ABCD2 regulation to cellular cholesterol/lipid sensing, with functional consequences for VLCFA clearance.\",\n      \"evidence\": \"Reporter assays, site-directed mutagenesis, gel-shift, and VLCFA measurement in X-ALD fibroblasts\",\n      \"pmids\": [\"12374760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of SREBP1 vs. SREBP2 isoforms unclear\", \"In vivo promoter occupancy not shown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Discovery of a functional TRE in the ABCD2 promoter and TRβ-dependent induction by T3 opened a pharmacological avenue for ABCD2 upregulation and linked thyroid hormone signaling to peroxisomal fatty acid metabolism.\",\n      \"evidence\": \"Gel-shift assay, TRβ knockout mice, T3 treatment of oligodendrocytes, β-oxidation assay in fibroblasts\",\n      \"pmids\": [\"12761339\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative roles of TRα vs. TRβ in different tissues not yet dissected\", \"In vivo therapeutic efficacy of T3-mediated ABCD2 induction not tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"In vivo genetic epistasis—ABCD2 overexpression preventing neurodegeneration in ABCD1 KO mice and double KO exacerbating disease—proved functional redundancy and established ABCD2 as a therapeutic target for X-ALD.\",\n      \"evidence\": \"Transgenic ABCD2 overexpression in ABCD1 KO mice and ABCD1/ABCD2 double KO mice with neuropathology and VLCFA quantification\",\n      \"pmids\": [\"15489218\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of substrate channeling between ABCD1 and ABCD2 unknown\", \"Whether human disease severity correlates with ABCD2 expression levels not established\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Characterization of ABCD2 KO mice revealed a specific late-onset neurodegenerative phenotype (cerebellar/sensory ataxia with organelle damage) distinct from ABCD1 loss, demonstrating non-redundant physiological roles.\",\n      \"evidence\": \"ABCD2 KO mouse with neuropathology, electron microscopy, and VLCFA quantification\",\n      \"pmids\": [\"16223892\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which specific VLCFA species drive the organelle damage not defined\", \"Whether the late-onset phenotype reflects substrate specificity differences vs. tissue expression differences is unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identification of LXRα as a repressor acting through an overlapping SRE/DR-4 element explained tissue-specific discordance between SREBP activation and ABCD2 induction (e.g., liver vs. adipose).\",\n      \"evidence\": \"LXRα/β KO mice, fasting-refeeding/cholesterol loading, EMSA, reporter assays\",\n      \"pmids\": [\"16249184\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LXR repression is relevant in neural tissues not tested\", \"Structural basis of competitive SRE/DR-4 occupancy unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Reconstitution in yeast defined the substrate specificity of ABCD2 (C22:0, C22:6, C24:6) as distinct from ABCD1 (C24:0, C26:0), resolving why the two transporters are not fully interchangeable.\",\n      \"evidence\": \"Heterologous expression in S. cerevisiae pxa1/pxa2 double mutant with radiolabeled fatty acid β-oxidation assays\",\n      \"pmids\": [\"21145416\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether substrate preference holds for CoA-ester forms in mammalian membranes not confirmed\", \"No structural explanation for selectivity\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Physical interaction between ABCD1 and ABCD2 was demonstrated by two orthogonal methods, and a dominant-negative ABCD2 mutant impaired ABCD1 function, proving heterodimer formation is functionally relevant.\",\n      \"evidence\": \"Proximity ligation assay and co-immunoprecipitation with ATPase-dead ABCD2-EGFP mutant; β-oxidation assays\",\n      \"pmids\": [\"21209459\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and relative abundance of homodimers vs. heterodimers in vivo unknown\", \"No structural model of the heterodimer\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of β-catenin/TCF-4 as a direct transcriptional activator of ABCD2 via promoter TCF-4 elements expanded the signaling inputs regulating peroxisomal VLCFA import beyond nuclear receptor pathways.\",\n      \"evidence\": \"ChIP, site-directed mutagenesis of TCF-4 elements, reporter assay, VLCFA measurement\",\n      \"pmids\": [\"23437103\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological context in which Wnt/β-catenin regulates ABCD2 in vivo not defined\", \"Cross-talk between TCF-4 and SREBP/LXR pathways at the promoter not explored\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"AMPKα1 was established as a required upstream kinase for ABCD2 induction (e.g., by metformin), linking cellular energy sensing to peroxisomal VLCFA transport.\",\n      \"evidence\": \"AMPKα1 KO glial cells, metformin treatment in ABCD1 KO mice in vivo, western blotting\",\n      \"pmids\": [\"26849413\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct AMPKα1 phosphorylation target(s) mediating ABCD2 induction unknown\", \"Whether AMPK acts through SREBP or an independent pathway not resolved\", \"Single lab finding\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis for ABCD2 substrate selectivity, the stoichiometry of ABCD1–ABCD2 heterodimers in different tissues, and the identity of the specific lipid signals driving organelle damage upon ABCD2 loss remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of ABCD2 or ABCD1–ABCD2 heterodimer\", \"Lipid species causally responsible for mitochondrial/ER/Golgi damage in ABCD2 KO not identified\", \"Therapeutic translation of ABCD2 induction strategies to human X-ALD not tested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [9, 16, 18]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [1, 6, 12, 16, 18, 20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005777\", \"supporting_discovery_ids\": [0, 1, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [1, 6, 12, 16, 17, 18, 20]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [6, 12, 16, 20]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 5, 8, 14, 19]}\n    ],\n    \"complexes\": [\n      \"ABCD1-ABCD2 heterodimer\",\n      \"ABCD2 homodimer\"\n    ],\n    \"partners\": [\n      \"ABCD1\",\n      \"SREBF1\",\n      \"THRA\",\n      \"THRB\",\n      \"NR1H3\",\n      \"CTNNB1\",\n      \"TCF7L2\",\n      \"PRKAA1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"ABCD2 is a peroxisomal half-ABC transporter that imports very long-chain and polyunsaturated fatty acid CoA-esters—particularly C22:6 (DHA), C22:0, and monounsaturated VLCFA—into peroxisomes for β-oxidation, functioning as a homodimer or heterodimer with ABCD1 [PMID:21145416, PMID:21209459]. ABCD2 is functionally redundant with ABCD1 for saturated VLCFA transport, as transgenic ABCD2 overexpression prevents VLCFA accumulation and neurodegeneration in Abcd1-knockout mice, while Abcd1/Abcd2 double knockout produces synergistically severe disease [PMID:15489218, PMID:25255441]. Loss of ABCD2 alone causes late-onset cerebellar and sensory ataxia with Purkinje cell loss, VLCFA accumulation, and mitochondrial/ER/Golgi damage, and uniquely disrupts adrenal oxidative homeostasis and adipose monounsaturated VLCFA clearance [PMID:16223892, PMID:17260006, PMID:19556607]. ABCD2 transcription is activated by SREBP via a promoter SRE element, by thyroid hormone receptors (TRα/TRβ) via an overlapping SRE/DR-4 motif, by β-catenin/TCF-4, and by AMPK α1-dependent signaling, while LXRα acts as a repressor competing at the same SRE/DR-4 site [PMID:12374760, PMID:18834645, PMID:16249184, PMID:23437103, PMID:26849413].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Cloning of ABCD2 established it as a peroxisomal half-ABC transporter paralog of ABCD1, raising the question of whether it could compensate for ABCD1 loss in X-ALD.\",\n      \"evidence\": \"cDNA cloning and sequence analysis showing 62.8% identity to ABCD1, tissue expression profiling\",\n      \"pmids\": [\"9345306\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional activity demonstrated\", \"Dimerization predicted but not tested\", \"Peroxisomal localization not directly confirmed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Direct localization to peroxisomes and functional complementation of VLCFA oxidation in ABCD1-deficient cells demonstrated that ABCD2 could substitute for ABCD1, answering the functional redundancy question at the cellular level.\",\n      \"evidence\": \"Subcellular fractionation, immunolocalization, and VLCFA oxidation rescue in X-ALD fibroblasts\",\n      \"pmids\": [\"10329405\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Substrate specificity unknown\", \"In vivo redundancy not tested\", \"Single lab observation\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of a functional SRE in the ABCD2 promoter revealed that sterol depletion via SREBP activates ABCD2 transcription, providing the first defined transcriptional regulatory mechanism and a pharmacological route to upregulate ABCD2 in X-ALD cells.\",\n      \"evidence\": \"Reporter assays, site-directed mutagenesis, EMSA, and VLCFA reduction in X-ALD fibroblasts upon sterol depletion\",\n      \"pmids\": [\"12374760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SREBP-mediated induction is sufficient in vivo to rescue disease unknown\", \"Contribution of other transcription factors at overlapping elements not yet mapped\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Discovery that thyroid hormone induces ABCD2 via TRβ binding to a promoter response element—with functional VLCFA normalization in ABCD1-deficient cells—established a second major transcriptional axis and raised the possibility of thyromimetic therapy.\",\n      \"evidence\": \"EMSA (RXR/TRβ binding), TRβ-knockout mice, cell-type specific induction in oligodendrocytes, β-oxidation assay in X-ALD fibroblasts\",\n      \"pmids\": [\"12761339\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CNS-relevant cell types respond sufficiently in vivo unknown\", \"TRα versus TRβ contributions not fully dissected\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"In vivo genetic epistasis using transgenic ABCD2 overexpression and Abcd1/Abcd2 double knockouts proved functional redundancy at the organismal level: ABCD2 prevented VLCFA accumulation and neurodegeneration, while combined loss accelerated disease with inflammation.\",\n      \"evidence\": \"Transgenic ABCD2 overexpression in Abcd1-KO mice; Abcd1/Abcd2 double KO with histopathology and VLCFA measurement\",\n      \"pmids\": [\"15489218\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degree of substrate overlap versus specificity not resolved\", \"Mechanism of inflammatory exacerbation in double KO unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Characterization of Abcd2-knockout mice revealed a non-redundant role: ABCD2 loss alone causes late-onset cerebellar/sensory ataxia with Purkinje cell degeneration and organelle damage, while LXRα was identified as a repressor competing with SREBP at overlapping SRE/DR-4 promoter elements.\",\n      \"evidence\": \"Abcd2-KO mouse phenotyping with electron microscopy and VLCFA measurement; LXRα/β-KO mice, EMSA, and reporter assays for promoter regulation\",\n      \"pmids\": [\"16223892\", \"16249184\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of organelle cross-talk damage unknown\", \"Relative in vivo contributions of SREBP versus LXR to tissue-specific expression not quantified\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defining the overlapping TRα/TRβ/SREBP interplay at the SRE/DR-4 element, combined with substrate profiling in knockout brain slices, established that ABCD2 has distinct preferred substrates (C22:0, monounsaturated VLCFA, DHA precursors) and that its transcriptional control integrates thyroid hormone and sterol signals at a single regulatory module.\",\n      \"evidence\": \"TRα-KO and TRβ-KO mice with EMSA and reporter assays; radiolabeled β-oxidation assays and fatty acid profiling in Abcd2-KO brain slices and primary neurons\",\n      \"pmids\": [\"18834645\", \"18854420\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transport assay with purified protein not performed\", \"Whether TR-SREBP interaction is direct or mediated by cofactors unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Yeast reconstitution definitively demonstrated that ABCD2 homodimers transport CoA-esters with specificity for C22:0, C24:6, and especially DHA (C22:6), distinct from ABCD1's preference for C24:0/C26:0, while adipose tissue studies revealed ABCD2 as the dominant peroxisomal transporter opposing monounsaturated VLCFA accumulation in fat.\",\n      \"evidence\": \"Functional complementation in S. cerevisiae pxa1/pxa2Δ with radiolabeled substrates; Abcd2-KO mice with dietary erucic acid challenge and quantitative fatty acid profiling in adipose\",\n      \"pmids\": [\"21145416\", \"19556607\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural basis for substrate discrimination\", \"Homodimer versus heterodimer substrate preferences not compared in the same system\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Physical interaction between ABCD1 and ABCD2 was demonstrated by proximity ligation assay and co-immunoprecipitation, with a non-functional ABCD2 exerting a transdominant-negative effect on ABCD1, confirming heterodimer formation and its functional relevance.\",\n      \"evidence\": \"PLA, co-IP, inducible expression of WT versus mutant ABCD2-EGFP, fatty acid profiling, β-oxidation assays\",\n      \"pmids\": [\"21209459\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural architecture of heterodimer unknown\", \"Whether heterodimer has distinct substrate specificity from either homodimer not determined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of β-catenin/TCF-4 as a direct transcriptional activator of ABCD2 via two promoter TCF-4 elements added a Wnt-responsive dimension to ABCD2 regulation, with functional VLCFA reduction upon ectopic β-catenin expression.\",\n      \"evidence\": \"ChIP confirming β-catenin binding, site-directed mutagenesis of TCF-4 elements, luciferase reporters, RT-PCR, VLCFA measurement\",\n      \"pmids\": [\"23437103\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological context of Wnt-dependent ABCD2 regulation (which tissues, when) not established\", \"Interplay with SREBP/LXR/TR at the same promoter region not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Metformin-induced ABCD2 upregulation was shown to require AMPKα1, as demonstrated by abrogation in AMPKα1-KO glial cells, establishing a metabolic-sensing kinase pathway for ABCD2 induction with potential therapeutic relevance for X-ALD.\",\n      \"evidence\": \"AMPKα1-KO mouse primary glial cells, metformin treatment in vitro and in vivo (Abcd1-KO mice), western blotting\",\n      \"pmids\": [\"26849413\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism linking AMPKα1 to ABCD2 promoter (which transcription factor is the effector) unknown\", \"Single lab; in vivo VLCFA reduction by metformin not demonstrated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"No high-resolution structure of ABCD2 exists, the molecular basis for its substrate selectivity over ABCD1 is structurally undefined, and the relative physiological contributions of ABCD2 homodimers versus ABCD1–ABCD2 heterodimers remain uncharacterized in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No cryo-EM or crystal structure of ABCD2\", \"In vivo stoichiometry of homo- versus heterodimer pools in different tissues unknown\", \"Whether ABCD2 transports substrates as CoA esters or free fatty acids in mammalian membranes not directly demonstrated with purified protein\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [9, 17]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [1, 6, 12, 17, 18]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [12, 16, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005777\", \"supporting_discovery_ids\": [0, 1, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:1430728\", \"supporting_discovery_ids\": [4, 12, 16, 17, 18, 20]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [1, 6, 17, 18]}\n    ],\n    \"complexes\": [\n      \"ABCD2 homodimer\",\n      \"ABCD1–ABCD2 heterodimer\"\n    ],\n    \"partners\": [\n      \"ABCD1\",\n      \"SREBF1\",\n      \"NR1H3\",\n      \"THRB\",\n      \"THRA\",\n      \"CTNNB1\",\n      \"TCF7L2\",\n      \"PRKAA1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}